With European Union funds, the firm is accelerating its go-to-market strategy for the PrePsia four-metabolite, mass spec-based blood test for preterm preeclampsia.

The acquisition provides Biocrates with complementary skills and technologies, enabling it to serve the metabolomics market as a total solutions provider, it said.

The deal increases Metabolon's access to the European market and builds on its goal of bringing the value of metabolomics globally, according its CEO John Ryals.

Researchers from the US and UK used a combination of genetic and metabolomics analyses to home in on methylthioadenosine as sepsis biomarker.